Your browser doesn't support javascript.
loading
Development of a Chip/Chip/SRM platform using digital chip isoelectric focusing and LC-Chip mass spectrometry for enrichment and quantitation of low abundance protein biomarkers in human plasma.
Rafalko, Agnes; Dai, Shujia; Hancock, William S; Karger, Barry L; Hincapie, Marina.
Afiliação
  • Rafalko A; Barnett Institute of Chemical and Biological Analysis and Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States.
J Proteome Res ; 11(2): 808-17, 2012 Feb 03.
Article em En | MEDLINE | ID: mdl-22098410
ABSTRACT
Protein biomarkers are critical for diagnosis, prognosis, and treatment of disease. The transition from protein biomarker discovery to verification can be a rate limiting step in clinical development of new diagnostics. Liquid chromatography-selected reaction monitoring mass spectrometry (LC-SRM MS) is becoming an important tool for biomarker verification studies in highly complex biological samples. Analyte enrichment or sample fractionation is often necessary to reduce sample complexity and improve sensitivity of SRM for quantitation of clinically relevant biomarker candidates present at the low ng/mL range in blood. In this paper, we describe an alternative method for sample preparation for LC-SRM MS, which does not rely on availability of antibodies. This new platform is based on selective enrichment of proteotypic peptides from complex biological peptide mixtures via isoelectric focusing (IEF) on a digital ProteomeChip (dPC) for SRM quantitation using a triple quadrupole (QQQ) instrument with an LC-Chip (Chip/Chip/SRM). To demonstrate the value of this approach, the optimization of the Chip/Chip/SRM platform was performed using prostate specific antigen (PSA) added to female plasma as a model system. The combination of immunodepletion of albumin and IgG with peptide fractionation on the dPC, followed by SRM analysis, resulted in a limit of quantitation of PSA added to female plasma at the level of ∼1-2.5 ng/mL with a CV of ∼13%. The optimized platform was applied to measure levels of PSA in plasma of a small cohort of male patients with prostate cancer (PCa) and healthy matched controls with concentrations ranging from 1.5 to 25 ng/mL. A good correlation (r(2) = 0.9459) was observed between standard clinical ELISA tests and the SRM-based assay. Our data demonstrate that the combination of IEF on the dPC and SRM (Chip/Chip/SRM) can be successfully applied for verification of low abundance protein biomarkers in complex samples.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Espectrometria de Massas / Proteínas Sanguíneas / Cromatografia Líquida / Análise Serial de Proteínas / Focalização Isoelétrica Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: J Proteome Res Assunto da revista: BIOQUIMICA Ano de publicação: 2012 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Espectrometria de Massas / Proteínas Sanguíneas / Cromatografia Líquida / Análise Serial de Proteínas / Focalização Isoelétrica Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: J Proteome Res Assunto da revista: BIOQUIMICA Ano de publicação: 2012 Tipo de documento: Article País de afiliação: Estados Unidos